An advisory committee that reviews drug applications for the US Food and Drug Administration has concluded that the Alzheimer’s disease treatment Leqembi (lecanemab) has shown clinical benefit for patients and should be approved. The Peripheral and Central Nervous System Drugs Advisory Committee voted unanimously to recommend full approval on 9 June. A decision by the FDA is expected on 6 July.
